Document is current
Any future updates will be listed below
-
Authors
Leleu, Xavier https://orcid.org/0000-0002-9822-4170
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore https://orcid.org/0000-0003-0131-8689
Karlin, Lionel
Roussel, Murielle
Montes, Lydia
Cherel, Brieuc
Chalopin, Thomas
Slama, Borhane
Chretien, Marie-Lorraine
Laribi, Kamel
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Calmettes, Claire
Dib, Mamoun
Tiab, Mourad
Vincent, Laure
Delaunay, Jacques
Santagostino, Alberto
Macro, Margaret
Bourgeois, Emmanuelle
Orsini-Piocelle, Frederique
Gay, Julie
Bareau, Benoit
Bigot, Noemie
Vergez, François
Lebreton, Pierre
Tabrizi, Reza
Waultier-Rascalou, Agathe
Frenzel, Laurent
Le Calloch, Ronan
Chalayer, Emilie
Braun, Thorsten
Lachenal, Florence
Corm, Selim
Kennel, Celine
Belkhir, Rakiba
Bladé, Jean-Sebastien
Joly, Bertrand
Richez-Olivier, Valentine
Gardeney, Helene
Demarquette, Helene
Robu-Cretu, Daniela
Garderet, Laurent
Newinger-Porte, Muriel
Kasmi, Amine
Royer, Bruno
Decaux, Olivier
Arnulf, Bertrand
Belhadj, Karim
Touzeau, Cyrille
Mohty, Mohamad
Manier, Salomon
Moreau, Philippe
Avet-Loiseau, Hervé
Corre, Jill https://orcid.org/0000-0003-1580-6106
Facon, Thierry
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 8 May 2024
First Online: 3 June 2024
Competing interests
: The authors report the following competing interests. X.L. has received consultancy, honoraria and travel fees from Sanofi, Janssen-Cilag, Kite/Gilead, Amgen, Novartis, Takeda, Pfizer, Oncopeptide, AbbVie, GSK and Bristol Myers Squibb. C.H. reports consultancy and honoraria from Janssen-Cilag. A.B. received consultancy and honoraria from Sanofi, Janssen-Cilag. A.P. reports receiving consultancy, honoraria and travel fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, GSK, Menarini Stemline, Pfizer, Sanofi and Takeda. L.K. has received consultancy, honoraria and travel fees from Sanofi, Janssen-Cilag, Kite/Gilead, Amgen, Novartis, Takeda, Pfizer, Oncopeptide, AbbVie, GSK and Bristol Myers Squibb. T.C. reports receiving consultancy fees and honoraria from Sanofi and Janssen-Cilag. C.T. has received consultancy, honoraria and travel fees from Sanofi, Janssen-Cilag, Kite/Gilead, Amgen, Novartis, Takeda, Pfizer, Oncopeptide, AbbVie, GSK and Bristol Myers Squibb. M.M. has received consultancy, honoraria and travel fees from Sanofi, Janssen-Cilag, Kite/Gilead, Amgen, Novartis, Takeda, Pfizer, Oncopeptide, AbbVie, GSK and Bristol Myers Squibb. P.M. reports consultancy fees and honoraria from Janssen-Cilag, Amgen, Novartis, Takeda, Pfizer, AbbVie, GSK, Bristol Myers Squibb and Sanofi. H.AL. has received consultancy, honoraria and travel fees from Janssen, Sanofi, Bristol Myers Squibb, Pfizer and Adaptive, and research support from Sanofi and Bristol Myers Squibb. J.C. reports consultancy, honoraria and travel fees from Janssen, Sanofi, Bristol Myers Squibb, Pfizer and Adaptive, and research support from Sanofi and Bristol Myers Squibb. The other authors declare no competing interests.
